(For cancer survivors, patients and health care practitioners)
On Thursday, December 5th at 6:30 pm Dr. Janos Tanyi, MD, PhD, Surgeon and Assistant Professor of Obstetrics and Gynecology at the University of Pennsylvania Abramson’s Cancer Center’s Perelman Center for Advanced Medicine and Principal Investigator will be at Gilda’s Club Delaware Valley. Dr. Tanyi will explain how Penn Medicine’s two-step personalized immunotherapy treatment works. In the first step, the patient’s own dendritic cells and tumor cells are used to generate a personalized vaccine which can kill her own tumor. In step two, the patient’s T-cells trigger an anti-tumor immune response that kills cancer cells.
The trial vaccine study’s lead author, Lana Kandalaft, PharmD, PhD, MTR, Research Assistant Professor of Obstetrics and Gynecology and Director of Clinical Development and Operations in Penn Medicine’s Ovarian Cancer Research Center explained, “This is the first time such a combination immunotherapy approach has been used for patients with ovarian cancer and we believe the results are leading us toward a completely new way to treat this disease”. Patients with advanced ovarian cancer whose five-year survival rate is normally under 30% were treated with this personalized cancer vaccine are clearly benefiting from this immunotherapy combination"
Patients for the study are currently being recruited.
If you’d like to attend, please call Gilda’s Club at 215.441.3290 to reserve a seat. The event is free.
Gilda's Club on Facebook:https://www.facebook.com/events/711472728862909/
Autologous OC-DC Vaccine in Ovarian Cancer:http://clinicaltrials.gov/ct2/show/NCT01132014?term=dendritic+cell+vaccine+ovarian&rank=7
Biologic Therapy/Immunotherapy at Penn Medicine: http://www.penncancer.org/patients/cancer-treatment-at-penn/biologic-therapy-immunotherapy/